教室紹介

2017年業績集

受賞

  1. 吉田 宗一郎.　東京医科歯科大学医学研究奨励賞

  2. 矢嶋 習吾、吉田 宗一郎、横山 みなと、石岡 淳一郎、松岡 陽、齋藤 一隆、藤井 靖久. 全身拡散強調MRIが活動性骨転移病巣の同定と治療効果の判定に有用であった去勢抵抗性前立腺癌の2例.「第623回日本泌尿器科学会東京地方会ベストプレゼンテーション賞」日本泌尿器科学会東京地方会、2017年2月16日

原著

  1. Waseda Y, Yoshida S, Takahara T, Kwee TC, Matsuoka Y, Saito K, Kihara K, Fujii Y. Utility of computed diffusion-weighted MRI for predicting aggressiveness of prostate cancer. J Magn Reson Imaging, 46(2): 490-6, 2017.PubMed

  2. Nakamura Y, Yoshida S, Tanaka H, Inoue M, Ito M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K. Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection. Urol Int, 98(3): 298-303, 2017.PubMed

  3. Nishizawa T, Yoshida S, Koga F, Tanaka H, Kaga M, Watanabe K, Fukushima H, Nakanishi Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K. Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes.Clin Imaging, 44: 121-126, 2017. PubMed

  4. Tanaka H, Fujii Y, Ishioka J, Matsuoka Y, Saito K, Kihara K. Absence of renal artery pseudoaneurysm on computed tomography after minimally-invasive partial nephrectomy using clampless and sutureless techniques. Int J Urol. 2017; 24: 472-3.PubMed

  5. Tanaka H, Fujii Y, Tanaka H, Ishioka J, Matsuoka Y, Saito K, Uehara S, Numao N, Yuasa T, Yamamoto S, Masuda H, Yonese J, Kihara K. Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation. Int J Urol. 2017; 24: 511-7.PubMed

  6. Saito K, Fujii Y. Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients. Eur Urol, 2017. PubMed

  7. Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol, 22(6): 1081-6, 2017. PubMed

  8. Matsuoka Y, Ishioka J, Tanaka H, Kimura T, Yoshida S, Saito K, Fujii Y, Kihara K. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer. AJR Am J Roentgenol, 209(2): 76-84, 2017. PubMed

  9. Yoshida S, Fukuyo T, Saito K, Kihara K, Fujii Y. Real-time three-dimensional image angle rectification to improve hand-eye coordination in single-port laparoendoscopic surgery. Int J Urol, 24(8): 639-40, 2017. PubMed

  10. Yoshida S, Takahara T, Kwee TC, Waseda Y, Kobayashi S, Fujii Y. DWI as an Imaging Biomarker for Bladder Cancer. AJR Am J Roentgenol, 208(6): 1218-28, 2017. PubMed

  11. Fukushima H, Kobayashi M, Kawano K, Morimoto S. Effect of Preoperative Bacteriuria and Pyuria on Intravesical Recurrence in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy. In Vivo, 31(6): 1215-20, 2017. PubMed

  12. Fukushima H, Kobayashi M, Kawano K, Morimoto S. Performance of Quick Sequential (Sepsis Related) Organ Failure Assessment and Sequential (Sepsis Related) Organ Failure Assessment to Predict Mortality in Patients with Acute Pyelonephritis Associated with Upper Urinary Tract Calculi. J Urol, 2017. PubMed

総説

  1. Yoshida S, Takahara T, Kwee TC, Waseda Y, Kobayashi S, Fujii Y. DWI as an Imaging Biomarker for Bladder Cancer.AJR Am J Roentgenol, 28: 1-11, 2017. linkPubMed

学会発表

欧州泌尿器科学会（The 32th European Association of Urology annual congress, London, UK）

  1. Matsuoka Y, Ishioka J, Tanaka H, Kimura T, Inoue M, Ito M, Kijima T, Yoshida S, Yokoyama M, Saito K, Kihara K, Fujii Y. Characteristics of MRI staging using PI-RADS version 2 and its predictive performance for biochemical recurrence after radical prostatectomy compared to PI-RADS version 1. 2017/3/27

  2. Kawamura N, Yokoyama M, Nakayama T, Tanaka H, Inoue M, Ito M, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Acute kidney injury after clampless partial nephrectomy: Incidence, predictors, and its low impact on intermediate-term renal function. 2017/3/27

  3. Izumi K, Saito K, Nakayama T, Fukuda S, Fukushima H, Uehara S, Koga F, Yonese J, Kageyama Y, Kihara K, Fujii Y.. Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell carcinoma. 2017/3/26

  4. Komai Y, Gotohda N, Sakai Y, Ito M. Preliminary kidney parenchymal ligation to achieve trifecta in zero-ischemia laparoscopic partial nephrectomy. 2017/3/25

  5. Nakamura Y, Tanaka H, Fujii Y, Inoue M, Ito M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K. Bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: A comparison of oncological outcomes between primary and progressive diseases. 2017/3/27

米国泌尿器科学会（The 112th annual meeting of the American Urological Association, Boston, USA）

  1. Ishioka J, Matsuoka Y, Itoh M, Inoue M, Kijima T, Yoshida S, Yokoyama M, Saito K, Kihara K, Fujii Y, Tanaka H, Kimura T. Computer-aided diagnosis of prostate cancer using a deep neural networks algorithm in pre-biopsy multiparametric magnetic resonance imaging. 2017/5/12

  2. Yokoyama M, Koga F, Otsuka Y, Tsukamoto T, Okuno T, Nagahama K, Kageyama Y, Noro A, Tsujii T. Impact of chronic kidney disease and hypertension on decline in remaining kidney function after radical nephrectomy. 2017/5/15

  3. Ito M, Inoue M, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Noboru Numao, Matsuoka Y, Saito K, Kihara K, Fujii Y. Short-term androgen deprivation therapy increases brain-type natriuretic peptide levels in patients with prostate cancer: Possible adverse impact on cardiac function. 2017/5/14

  4. Inoue M, Yasuhisa Fijii, Ito M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K. Incidence and risk factors of postoperative hypertension after partial nephrectomy for renal tumors. 2017/5/14

  5. Nakayama T, Saito K, Waseda Y, Tanaka H, Inoue M, Ito M, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Kihara K, Fujii Y. Immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. 2017/5/13

  6. Nakayama T, Kijima T, Yoshida S, Koga F, Kihara K, Fujii Y. Zoledronic acid sensitizes castration-resistant prostate cancer cells to radiotherapy and chemotherapy by downregulating STAT1. 2017/5/15

  7. Yasuda Y, Saito K, Kawamura N, Uehara S, Yuasa T, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Takahashi S, Okuno T. Protein predicts survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. 2017/5/12

  8. Waseda Y, Inoue M, Ito M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. New predictive scoring model for recurrence incorporating bladder neck involvement in patients with non-muscle-invasive bladder cancer. 2017/5/12

  9. Waseda Y, Saito K, Inoue M, Ito M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Kihara K, Fujii Y. Predictive ability of renal cortex enhancement in dynamic CT for residual renal function after nephroureterectomy: Comparative study with renography. 2017/5/15

  10. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Post-therapeutic recovery of skeletal muscle mass predicts favorable prognosis in advanced urothelial carcinoma patients receiving 1st-line platinum-based chemotherapy. 2017/5/12

  11. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of serum γ-glutamyltransferase in advanced urothelial carcinoma patients. 2017/5/13